Immunome, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Immunome, Inc. (IMNM) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $366.00 thousand as of 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2021-05-12
- 2021-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $366.00K.
- 2020-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $55.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2021-03-31 | $366.00K 10-Q · filed 2021-05-12 |
| 2020-09-30 | $55.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |